| Drug Name: | Digoxin (20830-75-5) |
|---|---|
| PubChem ID: | 2724385 |
| SMILES: | C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O |
| InchiKey: | LTMHDMANZUZIPE-PUGKRICDSA-N |
| Therapeutic Category: | Anti-Arrhythmia Agents, Cardiotonic Agents, Cardiovascular Agents, Enzyme Inhibitors, Protective Agents |
| Molecular Weight (dalton) | : | 780.949 |
| LogP | : | 2.2181 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 14 |
| Hydrogen Bond Donor Count | : | 6 |
| Total Polar Surface Area | : | 203.06 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Mitochondrial Defects | 3-hydroxy-3-methylglutaryl-coenzyme A reductase (P04035) | Elevation in plasma HMG CoA reductase activity, which induced alteration in intracellular calcium/magnesium ratios and low ubiquinone levels can lead to a mitochondrial dysfunction [ ADR Type 1 ] | Hypothalamic digoxin mediated model for oncogenesis |
| Mitochondrial Defects | Sodium/potassium-transporting ATPase (P05023) | Membrane Na+-K+ ATPase inhibition due to elevated diGOxin@which induced alteration in intracellular calcium/magnesium ratios and low ubiquinone levels can lead to a mitochondrial dysfunction [ ADR Type 1 ] | Hypothalamic digoxin mediated model for oncogenesis |
| Myelosuppression | Multidrug resistance protein 1 (P08183) | Myelosuppression [ ADR Type 1 ] | Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele |
| Oncogenesis | Caspase-3 (P42574) | DiGOxin induced alteration in intracellular calcium/magnesium ratios and low ubiquinone levels can lead to a mitochondrial dysfunction resulting in increased free radical generation and reduced scavenging & caspase-3 activation producing a P21 defect contributing to oncogenesis [ ADR Type 2 ] | Hypothalamic digoxin mediated model for oncogenesis |
| Oncogenesis | P21 protein (P78460) | Digoxin induced alteration in intracellular calcium/magnesium ratios and low ubiquinone levels can lead to a mitochondrial dysfunction resulting in increased free radical generation and reduced scavenging & caspase-3 activation producing a P21 defect contributing to oncogenesis. [ ADR Type 2 ] | Hypothalamic digoxin mediated model for oncogenesis |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Grapefruit Juice | Chf | Grapefruit juice and drug interactions Exploring mechanisms of this interaction and potential toxicity for certain drugs |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category